Real-world Clinical Response to Trazodone in Italy, Poland, and Romania

Prior treatment

• Concomitant treatment with other antidepressant drugs, mood stabilizers, antipsychotics, and/or proved resistance to trazodone monotherapy.
• Patients with previous or current history of any neurological condition that, in the opinion of the Investigator, might compromise participation in the study.
• Patients participating in any interventional study in the 30 days prior to the enrolment visit.

Other illness

• Known hypersensitivity or allergy to the active ingredient and/or to any component of the study medication.
• Patients with current diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, severe personality disorder, mental retardation, organic mental disorders, or mental disorders due to a general medical condition.

Other

• Patients who meet any of the contraindications to the administration of trazodone according to the approved local SmPC.
• Patients with ongoing pregnancy or breast-feeding at enrolment visit.

• Patients aged 55 or older.
• Patients who meet the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria for MDD diagnosis.
• Patients experiencing a current major depressive episode of at least moderate severity, defined by a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≥20 at enrolment.
• Patients with a diagnosis of MCI (also referred to as "mild neurocognitive disorder") according to the DSM-5 criteria.
• Patients who start treatment with trazodone hydrochloride (prolonged release) with starting dosage according to SmPC at enrolment visit (or at latest within one week).
• Patients legally capable of giving their written consent to participate in the study (including personal data processing) and willing to comply with all study procedures as per clinical judgement.